Scientific Advisory Board
Mohamed Sayegh, MD
Dr. Sayegh currently holds the title of Associate Professor
of Medicine at Harvard Medical School where
he is active in both clinical and research activities in transplantation.
He received his M.D. from the American University of Beirut,
completed his residency in Internal Medicine at the Cleveland
Clinic Foundation, and his fellowship in nephrology and transplantation
immunobiology at Harvard Medical School,
Brigham and Women's Hospital. Dr. Sayegh is the Research Director
of the Laboratory of Immunogenetics and Transplantation at the
Brigham and Women's Hospital and research director of the Nephrology
Division at Children's Hospital in Boston, MA. He is a world-recognized leader in transplantation.
He is past President of the American Society of Transplantation.
He has published more than 150 original articles.
Brian Barber, PhD
Dr. Barber, currently Vice President, Global Ventures, University
Health Network Development Corporation, is the former Chief Scientific
Officer and Senior Vice President of Mojave Therapeutics Inc.
Prior to joining Mojave he was the Assistant Vice President of
Immunology at Aventis Pasteur. At Aventis, Dr. Barber developed
the newly formed Immunology Platform in Research into a center
of excellence in human cellular immunology, and was instrumental
in the establishment of a 30,000 sq. ft. research facility for
Aventis Pasteur's cancer vaccine program. Previously, Dr. Barber
spent 20 years as a professor in the Department of Immunology,
Faculty of Medicine at the University of Toronto,
with cross-appointments to the University of Toronto's Institute of Medical
Sciences and The Toronto Hospital's
Division of Infectious Diseases. He received his Ph.D. from the
Department of Medical Biophysics at the University of Toronto.
This was followed by post-doctoral research at the Imperial Cancer
Research Fund and the National Institute of Medical Research,
both located in London, England.
Vijay Kuchroo, DVM, PhD
Dr. Kuchroo currently holds the position of Associate Professor
of Neurology at Harvard Medical School with
a cross-appointment as Associate Immunologist at the Brigham
and Women’s Hospital, Boston, MA. He has made significant research and teaching
contributions to the field of autoimmunity, having published
over 100 articles on the subject in high profile journals such
as the Journal of Experimental Medicine, Cell, Immunity, Nature,
Science and Journal of Immunology. He also acts as section editor
for the Journal of Immunology, and is on the editorial boards
of the journals Cellular Immunology and Autoimmunity. He serves
on the grant review panels of the Juvenile Diabetes Research
Foundation and National Multiple Sclerosis society. His current
research is focused on elucidating the genetic and cellular mechanisms
of autoimmune diseases and molecular mechanisms of T cell differentiation.
During his post-doctoral years, Dr. Kuchroo worked on deciphering
mechanisms of immune suppression at the NIH National Cancer Institute
in Maryland, and in the Department
of Pathology at Harvard Medical School in Boston.
He received his Ph.D. from the Department of Pathology and Public
Health at the University of Queensland in Australia and
his DVM from the College of Veterinary Medicine at Haryana Agricultural University, Hisar, India.
Marc Feldmann, MD, PhD
Dr. Feldmann is Head of Kennedy Institute of Rheumatology Division
at the Imperial College, London and is a world leader in cytokine research. He
and Professor Sir Ravinder Maini discovered the important role
of TNF alpha in the pathogenesis of rheumatoid arthritis. Their
work has paved the way for today's blockbuster TNF-blocking drugs
that are now used in a variety of autoimmune disorders. Dr.
Feldmann has authored over 600 scientific articles, has written
and edited numerous books and serves on the editorial boards
of a variety of scientific journals. He is the recipient
of many awards, including the 2000 Crafoord Prize of the Royal Swedish Academy of
Sciences and the 2003 Albert Lasker Clinical Research Award for
the discovery of anti-TNF therapy as an effective treatment for
rheumatoid arthritis and other autoimmune diseases. He
is an inventor on many patents and is the founder of the 2001
start-up company, Synovis. He received both his medical
degree and his Ph. D. degree from the University of Melbourne,
Australia.
|
